Research in contextEvidence before this studySecondary autoimmune disorders (sAID) are the most relevant risk related to alemtuzumab treatment in RRMS patients and thyroid sAID are by far the most common. However, biomarkers indicating increased risk for sAID in clinical routine are currently missing. We searched PUBMED, SCOPUS and COCHRANE databases from inception until May 21st 2019. In addition, ECTRIMS and ACTRIMS conference abstracts as well as reference lists of published articles were screened for further articles to be included. We combined search terms for multiple sclerosis, alemtuzumab, secondary autoimmune disorders, thyroid autoantibodies and thyroid autoimmunity. There were no language restrictions.IL-21 serum levels were proposed as a biomarker for the risk of developing autoimmunity post alemtuzumab, however currently available detection kits show no predictive utility. A retrospective case-control-study demonstrated that anti-thyroid autoantibodies (ThyAb) precede the development of clinical overt thyroid autoimmune disorders in putative healthy controls. Two retrospective analyses of the CAMMS223 and a Welsh cohort support the indicative value of ThyAb for alemtuzumab-related thyroid sAID. However, data from prospective studies are missing.Added value of this studyTo our knowledge, this is the first study providing evidence for ThyAb detected by standard-testing as valuable tool for risk-estimation prior to alemtuzumab therapy from a prospective, multicentre observational study cohort. We found that anti-thyroglobulin (anti-TG) and anti--thyroid-peroxidase (anti-TPO) autoantibodies yielded good to strong performance for risk-estimation. ThyAb positivity was associated with a highly increased risk for and a shorter time to thyroid sAID.Implications of all the available evidenceThyroid sAID following alemtuzumab is often delayed by several years and the ability to reliably estimate the risk of individual patients would facilitate risk-benefit considerations in clinical decisions and allow for targeted monitoring as well as possibly early intervention in alemtuzumab-treated patients. In female patients with active family planning this might be of special relevance since thyroid disorders display a particular risk. Since the ThyAb testing applied in this study is readily available at most clinics in the world, this study can immediately instruct and improve clinical practice. However, positive ThyAb at baseline should not preclude alemtuzumab treatment per se, but instruct the informed consent building process before treatment initiation.Alt-text: Unlabelled Box

1. Introduction {#s0020}
===============

Alemtuzumab is used for the treatment of active relapsing-remitting multiple sclerosis (RRMS) and depletes B- and T-lymphocytes followed by a prolonged repopulation phase with profound quantitative and qualitative changes within immunological networks. Secondary autoimmune disorders (sAID) following alemtuzumab treatment are common and fundamentally affect the risk-benefit ratio and clinical decisions \[[@bb0005]\]. Hence, there is an urgent need for biomarkers instructing risk-estimation for sAID. Thyroid sAID are the most common and affects approximately 38% to 41% of alemtuzumab-treated patients peaking in year 3 after therapy initiation \[[@bb0010], [@bb0015], [@bb0020]\].

The most frequent alemtuzumab-associated sAID are mainly B-cell- and autoantibody-driven \[[@bb0005]\]. Therefore, it is currently believed that the disproportionately high B-cell over T-cell recovery leads to unregulated expansion of autoreactive B cells and consequently to sAID. However, alopecia, haemophagocytic syndrome, sarcoidosis and vitiligo after alemtuzumab infusion, which are all T cell-mediated, have been reported and hint to a more complex pathogenesis \[[@bb0025], [@bb0030], [@bb0035], [@bb0040]\]. Previously, serum IL-21 concentrations have been shown to correlate with the incidence of sAID after alemtuzumab and were proposed as potential biomarker \[[@bb0045]\]. However, the findings have not been substantiated in larger prospective cohorts and currently available IL-21 ELISA kits were not able to predict sAID after alemtuzumab \[[@bb0050]\]. A recent small retrospective study using custom-made high-sensitivity anti-TSHR (anti-thyroidea-stimulating-hormone-receptor) testing demonstrated that baseline measurement of anti-TSHR and anti--thyroid-peroxidase (anti-TPO) autoantibodies indicated increased risk for thyroid sAID following alemtuzumab treatment \[[@bb0055]\]. However, data from prospective studies evaluating the prognostic value of anti-thyroid autoantibodies (ThyAb) for alemtuzumab-related thyroid sAID have been missing so far.

We therefore evaluated whether baseline ThyAb including anti-thyroglobulin (anti-TG) and anti-TPO by standard tests are able to instruct risk-assessment for thyroid sAID in a prospective cohort of 106 alemtuzumab treated patients.

2. Materials and methods {#s0025}
========================

2.1. Study design and participants {#s0030}
----------------------------------

All patients were recruited at the Departments of Neurology at the University Hospital Münster (59 patients), University Hospital Essen (28 patients) and the Clinics Osnabrück (19 patients) in Germany. Patients were recruited starting from 1st April 2014 to 1st October 2018. All patients who received alemtuzumab were approached to participate in the study and 106 of 128 (83%) patients agreed to participate. Alemtuzmab patients received pre-treatments including azathioprine, beta interferons, glatiramer acetate, teriflunomide, fingolimod, natalizumab, mitoxantron, and siponimod (within a clinical trial). All patients were included in our prospective PROGRAM^MS^ ("Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response") cohort study. Here, detailed clinical and MRI data are collected in combination with blood samples following established SOPs developed within the KKNMS (German competence network for multiple sclerosis). Patients are evaluated at baseline (before first course of alemtuzumab) and every 3 months thereafter including standardized neurological examination, assessments (e.g. EDSS, MSFC) and additional laboratory testing for a study duration of five years. In the current study anti-TG and anti-TPO are measured at baseline and thyroid sAID is monitored prospectively by clinical and laboratory assessments.

Alemtuzumab treatment and monitoring (creatinine, blood count and urine testing monthly and TSH every 3 months) was conducted according to summary of product characteristics (SmPC).

In case of clinical or laboratory signs indicating thyroid sAID patients were referred to a specialized endocrinologist. Diagnosis of Graves\' disease was defined by anti-TSHR positivity and hyperthyroidism/hypothyroidism; autoimmune thyroiditis was defined by anti-TPO positivity and hypothyroidism (including cases with transient hyperthyroidism).

None of our patients showed (clinical or laboratory) signs of thyroid dysfunction before alemtuzumab initiation, and all were negative for anti-TSHR.

This study was performed according to the Declaration of Helsinki and approved by the local ethics committee of the University of Münster (Ethik-Kommission der Ärztekammer Westfalen-Lippe und der Westfälischen Wilhelms-Universität Münster, 2014-398-f-S). All patients gave written informed consent. The manuscript conforms to the STROBE reporting standards for cohort studies.

2.2. Detection of anti-thyroid autoantibodies {#s0035}
---------------------------------------------

ThyAb were detected by ECLIA (ElectroChemiLumineszenzImmunAssay) on an automated Cobas® e801 analyzer (Roche) used in clinical routine in a blinded manner and in an independent certified laboratory. Analysis was performed using specific kits and following the manufacturer\'s instructions for anti-TG (Elecsys Anti-Tg, Roche; cut off \>15 IU/ml), anti-TPO (Elecsys Anti-TPO, Roche; cut off 15 IU/ml) and anti-TSHR (Elecsys Anti-TSHR, Roche; cut off \>1·1 IU/ml) testing.

2.3. Statistical analysis {#s0040}
-------------------------

Statistical analysis was performed using R 3.6.1. To determine development of thyroid sAID over time, we performed Cox proportional hazards model with the R packages survival and survminer \[[@bb0060]\]. First, we used a univariate Cox regression to evaluate the hazards over time for each thyroid antibody separately and combined. Next, we used a multivariate cox regression to adjust for possible confounders including sex, age, disease duration, number of previous DMT, type of last DMT, baseline disability (EDSS) and smoking history. Statistical significance of each variable was evaluated by the Wald statistic value and the predictive value by Harrell\'s c statistic (concordance index). The global *p*-value was determined by the likelihood ratio test. Statistical significance between survival curves was tested by pairwise log rank test adjusted for multiple testing by Benjamini-Hochberg\'s false discovery rate correction. A *p*-value below 0·05 was considered statistically significant.

3. Results {#s0045}
==========

We here present data of a safety-concern triggered interim analysis with a median follow-up of 36 months. Baseline characteristics demonstrated no significant differences between patients with or without thyroid sAID ([Table 1](#t0005){ref-type="table"}). 46/75 (61·3%) of patients without sAID and 21/29 (72·4%) with thyroid sAID were female. Patients in the no sAID versus the thyroid sAID group had a median age of 35 versus 33 years at alemtuzumab initiation, a median disease duration of 5 versus 6 years and both had a median of 2 previous disease-modifying therapies (DMTs). No DMT was found at significantly higher frequencies in those groups. The proportions of patients with higher disability (EDSS step ≥3) and history of smoking were comparable.Table 1Patient baseline characteristics.Table 1*No sAID (n* *=* *75)Thyroid sAID (n* *=* *29)p*Female patients, No (%)*46 (61.3)21 (72.4)0.36*[b](#tf0010){ref-type="table-fn"}Age at baseline, years, median (IQR)*35 (29--43)33 (27.5--39)0.52*[a](#tf0005){ref-type="table-fn"}Disease duration, years, median (IQR)*5 (2−10)6 (4--11)0.1*[a](#tf0005){ref-type="table-fn"}Previous disease-modifying therapies, No, median (IQR)*2 (1--3)2 (2--4)0.15*[a](#tf0005){ref-type="table-fn"}EDSS step ≥ 3 at baseline, No (%)*36 (48)15 (51.7)0.83*[b](#tf0010){ref-type="table-fn"}Months of follow-up, median (IQR)*35 (25--44)37 (32.5--52)0.06*[a](#tf0005){ref-type="table-fn"}History of smoking, No (%)*18 (24)8 (27.5)0.8*[b](#tf0010){ref-type="table-fn"}Last previous DMT, No (%)*0.28*[b](#tf0010){ref-type="table-fn"} Naïve*13 (17.3)2 (6.9)* Natalizumab (escalation)*29 (38.7)6 (20.7)* Fingolimod (escalation)*8 (10.7)11 (37.9)* Dimethyl fumarate (basic)*9 (12)2 (6.9)* Interferon-beta (basic)*8 (10.7)4 (13.8)* Glatiramer acetate (basic)*2 (2.7)3 (10.3)* Teriflunomide (basic)*3 (4)0 (0)* Other*3 (4)1 (3.4)*ThyAb serostatus at baseline, No (%)*\<0.001*[b](#tf0010){ref-type="table-fn"} TPO−; TG−*71 (94.7)15 (51.7)* TPO+; TG−*1 (1.3)3 (10.3)* TPO−; TG+*3 (4.0)4 (13.8)* TPO+; TG+*0 (0.0)7 (24.1)*Titer level in ThyAb + patients, IU/mL, median (IQR) Anti-TPO*61.175.3 (60--1064)n/a* Anti-TG*47.8 (37.1--65.2)84.1 (72.1--139)0.09*[^2][^3][^4]

31/106 (29·2%) patients developed sAID between 5 and 51 months following treatment initiation. While 29 patients presented with thyroid sAID, two patients developed non-thyroid sAID (vitiligo and immune-thrombocytopenia, respectively) and were therefore excluded from the analysis.

14/29 patients (48·3%) with thyroid sAID were positive for ThyAb at baseline (4× anti-TG, 3× anti-TPO, and 7× anti-TG + anti-TPO), whereas only 4/75 patients (5·3%) without sAID were ThyAb positive ([Table 1](#t0005){ref-type="table"}) so far. Autoantibody titres seemed to be higher in the thyroid sAID group however not reaching statistical significance. A multivariate Cox regression for time to thyroid sAID showed no significant coefficients for sex, age, disability, number and type of previous DMT, disease duration and smoking history ([Fig. 1](#f0005){ref-type="fig"}a--c) suggesting negligible impact on thyroid sAID development. In contrast, anti-TG and anti-TPO or both combined had statistically significant coefficients in the multivariate Cox regression. We evaluated each antibody separately and then combined. Performance of anti-TPO (hazard ratio 12.52, 95% CI 5.15--30.4) suggested slightly superior performance to anti-TG (hazard ratio 7.23, 95% CI 2.88--18.1) without reaching statistical significance ([Fig. 1](#f0005){ref-type="fig"}a--c). The combination of anti-TPO and anti-TG (hazard ratio 12.15, 95% CI 4.73--31.2) yielded almost similar performance as anti-TPO only. The predictive ability of the multivariate Cox regression model with anti-TG (concordance index 0.71), was slightly lower than anti-TPO (concordance index 0.74) and the combination of both (concordance index 0.76), however indicating overall good to strong models. Comparing the survival plots of each antibody set showed a statistical significance between anti-TG and/or anti-TPO presence and the absence of both, but no statistical significance between all other possible comparisons ([Fig. 1](#f0005){ref-type="fig"}d).Fig. 1Thyroid autoantibodies at baseline indicate increased risk for thyroid secondary autoimmunity following alemtuzumab treatment. Multivariate Cox proportional hazards model: forests plots of hazard ratios for time to thyroid sAID for age, sex, disability, number and type of previous disease modifying therapies (DMT), disease duration, smoking history and either (a) anti-TG (TG), (b) anti-TPO (TPO) or (c) both combined. (d) Survival plot displaying the cumulative hazard and patients at risk for time to thyroid sAID for each set of antibody. \* *p* \< .05, \*\* *p* \< .01, \*\*\* *p* \< .001. EDSS: expanded disability status scale.Fig. 1

ThyAb positivity was not associated with a specific disease entity of thyroid sAID, 14 patients developed autoimmune thyroiditis and 15 Graves\' disease. 6/14 (42·9%) with baseline ThyAb positivity versus 4/15 (26·7%) without needed radioiodine therapy and/or thyroidectomy for successful treatment, however not reaching statistical significance. Remarkably, baseline ThyAbs were associated with shorter time to sAID ([Table 2](#t0010){ref-type="table"}).Table 2Thyroid sAID patient characteristics stratified according to baseline antibody status.Table 2*ThyAb*^+^*ThyAb*^−^*p*Disease entity*0.715*[b](#tf0020){ref-type="table-fn"} Autoimmune thyroiditis*68* Graves\' disease*87*Treatment required*0.304*[b](#tf0020){ref-type="table-fn"} Levothyroxine*68* Levothyroxine + TPOI*23* Levothyroxine + TPOI + RIT*21* Levothyroxine + TPOI + surgery*43*Onset from baseline, months (IQR)*10 (8.75--15)23 (11−33)0.041*[a](#tf0015){ref-type="table-fn"}[^5][^6][^7]

4. Discussion {#s0050}
=============

sAID are common and the most relevant risk associated with alemtuzumab treatment in RRMS patients \[[@bb0005]\]. Therefore, biomarkers instructing risk-assessment for sAID are a big unmet need in clinical practice for alemtuzumab-related treatment decisions. This safety-triggered interim analysis of a multicentre, prospective cohort of alemtuzumab treated RRMS patients provides evidence that standard ThyAb-testing of anti-TPO and anti-TG antibodies at baseline is able to indicate increased risk for clinically manifest thyroid sAID. ThyAb positivity was not associated with a specific disease entity of thyroid sAID, but with shorter time to sAID.

Consistently, thyroid autoantibodies have been associated with hypothyroidism and autoimmune thyroid disease in individuals with a positive family history for these disorders \[[@bb0065],[@bb0070]\]. Moreover, a previous retrospective case-control study of 522 female US military personnel described that anti-TG, anti-TPO, and anti-TSHR precede the development of spontaneous thyroid autoimmunity and reported odds ratios between 4·6 and 25 two to five years prior diagnosis \[[@bb0075]\]. However, these studies were small, retrospective in design or in case of the study on female US military personnel comprised a highly selected population. Therefore, no sufficient data exist allowing for a direct comparison of risk associations between our data and the general population. However, a large Canadian cohort comparing 4192 MS patients with 20,940 healthy controls has shown comparable incidence (422·8 vs. 407·7 per 100,000 persons/year) and prevalence (9·51% vs. 8·56%) of autoimmune thyroid disease \[[@bb0080]\]. Of note, the prevalence of thyroid autoimmunity in alemtuzumab-treated MS patients accounts for 38--41% as stated above \[[@bb0015]\]. Therefore, alemtuzumab seems to be related to a highly increased risk for thyroid autoimmunity with fundamental pathophysiological differences compared to the natural history.

Concerning alemtuzumab, two retrospective analyses evaluated the risk-indicative value of ThyAb prior to alemtuzumab treatment for the development of thyroid sAID. The analysis of the phase II CAMMS223 patient cohort (median follow-up of 57·3 months) demonstrated anti-TPO positivity in patients with thyroid sAID at baseline, in contrast to our cohort, only in 11/73 patients (15%) \[[@bb0085]\]. However, in this study only anti-TPO were measured and patients included were treatment-naïve with disease duration lower than 36 months, potentially explaining the observed differences. In our cohort only 14% of patients were treatment naïve before alemtuzumab treatment, which might be a better representation of the current alemtuzumab prescription strategies in real-life \[[@bb0090]\].

In another smaller, retrospective cohort study using custom-made high-sensitivity anti-TSHR testing at baseline, anti-TSHR were present in 5/16 (31%) patients with thyroid sAID and in 0/14 (0%) without, supporting the indicative value of ThyAb at baseline \[[@bb0055]\]. In contrast, we used a standard electrochemiluminescence assay common in clinical routine. Moreover, anti-TSHR positive patients were excluded from the analysis since anti-TSHR are causatively involved in the pathogenesis of Graves\' disease therefore precluding inclusion in our study \[[@bb0070]\]. However, implementation of high-sensitivity anti-TSHR testing might further improve the value of baseline ThyAb for risk-estimation.

Remarkably, a higher proportion of patients needing radioiodine therapy and/or thyroidectomy for successful treatment were ThyAb positive at baseline potentially indicating a more severe disease course. However, differences were not statistical significant and need to be substantiated in larger studies or in the final analysis of our cohort.

Of note, thyroid disease represents particular risks in women who are pregnant and therefore prediction of thyroid sAID might especially instruct clinical decisions concerning alemtuzumab treatment in women with active family planning \[[@bb0095]\].

Strengths of our study are the prospective design and the use of standard ThyAb testing. Of note, the interim analysis, the relatively small cohort with only 29 positive thyroid sAID cases (as per the exploratory nature of the study) and potential centre effects might be limitations that should be considered for data interpretation. These limitations might also affect generalisability of our data, however real-life and trial cohorts of alemtuzumab-treated RRMS patients share many characteristics of our cohort \[[@bb0020],[@bb0090]\]. Since autoimmune thyroid disorders have been diagnosed \>7 years following the first alemtuzumab course our analysis might have missed further thyroid sAID cases becoming clinically manifest in the future \[[@bb0100]\].

Model performance of anti-TPO suggested slightly superior performance compared to anti-TG and the combination of anti-TPO and anti-TG yielded almost similar performance as anti-TPO only. However, since 4/29 (13·8%) patients developing thyroid autoimmunity were only anti-TG positive, we suggest a pragmatic approach testing both autoantibodies in clinical practice.

In conclusion, standard ThyAb-testing of anti-TPO and anti-TG at baseline was able to indicate increased risk for clinically manifest thyroid sAID and is therefore a valuable tool to facilitate risk-benefit considerations before alemtuzumab treatment initiation.

Funding sources {#s0055}
===============

The study was supported by the German Ministry of Education, Science, Research and Technology (01GI1603D, to TR and SGM; FKZ01FI1603A to HW and CCG), and the German Research Foundation (Collaborative Research Centre CRC TR128 "Initiating/Effector versus Regulatory Mechanisms in Multiple Sclerosis -- Progress towards Tackling the Disease" (project A09 to HW and CCG)). Funding sources had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Author contributions {#s0060}
====================

TR: design and concept of study, analysis and interpretation of data, writing of the manuscript. ASM: analysis, and interpretation of data, writing of the manuscript. SP: analysis and interpretation of data, critical revision of manuscript for important intellectual content. MH: critical revision of manuscript for intellectual important content and further statistical analysis of data. LK: critical revision of manuscript for intellectual important content. SW + CK patient recruitment, critical revision of manuscript for important intellectual content. CCG: study concept, interpretation of data, and critical revision of manuscript for intellectual content. HW + SGM: study concept and design, study supervision and critical revision of manuscript for intellectual content. All authors read and approved the final version of the manuscript.

Declaration of Competing Interest
=================================

Dr. Ruck reports grants from German Minitry of Education, Science, research and Technology during the conduct of the study; grants and personal fees from Sanofi Genzyme, personal fees from Biogen, personal fees and non-financial support from Merck Serono, personal fees from Roche, personal fees from Teva outside the submitted work. Dr. Schulte-Mecklenbeck reports grants from Novartis outside the submitted work. Dr. Pfeuffer reports personal fees and non-financial support from Sanofi Genzyme, personal fees from Biogen, personal fees and non-financial support from Merck Serono, personal fees from Mylan, grants from Diamed outside the submitted work. Dr. Heming has nothing to disclose. Dr. Klotz reports grants from Novartis, Merck, Biogen, personal fees from Novartis, Biogen, Sanofi Genzyme, Merck, Roche, Janssen, Teva, Santhera outside the submitted work. Dr. Kleinschnitz has nothing to disclose. Dr. Windhagen has nothing to disclose.

Dr. Gross reports grants from Collaborative Research Centre, grants from German Ministry of Education, Science, Research and Technology during the conduct of the study; personal fees from Sanofi Genzyme, personal fees from Biogen, personal fees from Bayer Health Care, personal fees from Novartis, personal fees from Euroimmun, personal fees from Mylan outside the submitted work. Dr. Wiendl reports grants from German Ministry of Education, Science, Reseach and Technology, grants from Collaborative Research Centre during the conduct of the study; personal fees from Biogen, Evgen, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Roche Pharma AG, Abbvie, Actelion, Cognomed, IGES, Johnson & Johnson, the Swiss Multiple Sclerosis Society, F. Hoffmann-La Roche Ltd., Gemeinnützige Hertie-Stiftung, TEVA, WebMD Global, Alexion, and Sanofi-Aventis, grants from German Ministry for Education and Research (BMBF), Deutsche Forschungsgesellschaft (DFG), Else Kröner Fresenius Foundation, Fresenius Foundation, Hertie Foundation, NRW Ministry of Education and Research, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, RE Children\'s Foundation, Biogen, GlaxoSmithKline GmbH, Roche Pharma AG, Sanofi-Genzyme outside the submitted work. Dr. Meuth receives honoraria for lecturing, and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS and Teva. His research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Else Kröner Fresenius Foundation, German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology and Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, Merck Serono, Novartis, ONO Pharma, Roche, and Teva.

The authors thank Daniela Roosterman, Lena Schünemann, Janine Meyer, and Maj Lisa Frankenberg for excellent technical assistance.

[^1]: Equal contribution.

[^2]: No: number; IQR: interquartile range; EDSS: expanded disability status scale; DMT: disease-modifying treatment.

[^3]: Significance evaluated using Mann-Whitney test.

[^4]: Significance evaluated using Fisher\'s exact test.

[^5]: TPOI: thyroperoxidase inhibitor; RIT: radioiodine therapy.

[^6]: Significance evaluated using Mann-Whitney test.

[^7]: Significance evaluated using Fisher\'s exact test.
